Jefferies Group set a $156.00 price objective on Alnylam Pharmaceuticals (NASDAQ:ALNY) in a research note published on Friday morning. The brokerage currently has a buy rating on the biopharmaceutical company’s stock.
A number of other equities analysts have also issued reports on ALNY. BMO Capital Markets decreased their price objective on Alnylam Pharmaceuticals from $165.00 to $160.00 and set an outperform rating for the company in a report on Friday. Nomura increased their price target on Alnylam Pharmaceuticals to $86.00 and gave the company a sell rating in a research note on Friday. Morgan Stanley decreased their price target on Alnylam Pharmaceuticals from $128.00 to $118.00 and set an equal weight rating for the company in a research note on Friday. B. Riley began coverage on Alnylam Pharmaceuticals in a research note on Wednesday, November 1st. They set a buy rating and a $240.00 price target for the company. Finally, Piper Jaffray Companies reaffirmed a buy rating and set a $182.00 price target on shares of Alnylam Pharmaceuticals in a research note on Sunday, January 7th. Three analysts have rated the stock with a sell rating, seven have issued a hold rating, fifteen have issued a buy rating and one has issued a strong buy rating to the stock. Alnylam Pharmaceuticals has an average rating of Buy and an average price target of $126.98.
Alnylam Pharmaceuticals (NASDAQ ALNY) opened at $117.30 on Friday. Alnylam Pharmaceuticals has a fifty-two week low of $44.50 and a fifty-two week high of $147.63. The stock has a market capitalization of $11,530.00, a P/E ratio of -21.68 and a beta of 2.68. The company has a debt-to-equity ratio of 0.14, a current ratio of 9.83 and a quick ratio of 9.83.
Alnylam Pharmaceuticals (NASDAQ:ALNY) last issued its quarterly earnings data on Thursday, February 8th. The biopharmaceutical company reported ($1.48) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.38) by ($0.10). Alnylam Pharmaceuticals had a negative return on equity of 48.88% and a negative net margin of 545.95%. The business had revenue of $37.90 million during the quarter, compared to the consensus estimate of $19.31 million. During the same period last year, the company earned ($1.32) earnings per share. The business’s quarterly revenue was up 116.6% compared to the same quarter last year. analysts anticipate that Alnylam Pharmaceuticals will post -5.69 earnings per share for the current fiscal year.
In other news, SVP Laurie Keating sold 6,249 shares of the stock in a transaction on Wednesday, December 20th. The stock was sold at an average price of $121.20, for a total value of $757,378.80. Following the completion of the sale, the senior vice president now owns 17,749 shares in the company, valued at $2,151,178.80. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, VP Michael Mason sold 36,745 shares of the stock in a transaction on Thursday, January 4th. The shares were sold at an average price of $131.59, for a total value of $4,835,274.55. Following the completion of the sale, the vice president now owns 6,352 shares of the company’s stock, valued at approximately $835,859.68. The disclosure for this sale can be found here. Insiders have sold a total of 220,409 shares of company stock valued at $28,667,017 in the last quarter. Insiders own 4.30% of the company’s stock.
Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Verition Fund Management LLC purchased a new stake in shares of Alnylam Pharmaceuticals in the second quarter valued at $1,060,000. Gotham Asset Management LLC purchased a new stake in shares of Alnylam Pharmaceuticals in the second quarter valued at $772,000. Bradley Foster & Sargent Inc. CT lifted its holdings in shares of Alnylam Pharmaceuticals by 100.1% in the third quarter. Bradley Foster & Sargent Inc. CT now owns 8,235 shares of the biopharmaceutical company’s stock valued at $968,000 after purchasing an additional 4,120 shares in the last quarter. WINTON GROUP Ltd purchased a new stake in shares of Alnylam Pharmaceuticals in the third quarter valued at $10,633,000. Finally, First Trust Advisors LP lifted its holdings in shares of Alnylam Pharmaceuticals by 25.3% in the third quarter. First Trust Advisors LP now owns 784,619 shares of the biopharmaceutical company’s stock valued at $92,185,000 after purchasing an additional 158,288 shares in the last quarter. Institutional investors own 88.59% of the company’s stock.
TRADEMARK VIOLATION WARNING: “Alnylam Pharmaceuticals (ALNY) Given a $156.00 Price Target at Jefferies Group” was originally reported by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are viewing this piece on another domain, it was copied illegally and republished in violation of US and international trademark & copyright laws. The correct version of this piece can be read at https://www.dispatchtribunal.com/2018/02/13/alnylam-pharmaceuticals-alny-given-a-156-00-price-target-at-jefferies-group.html.
About Alnylam Pharmaceuticals
Alnylam Pharmaceuticals, Inc is a biopharmaceutical company. The Company is engaged in the discovery, development and commercialization of ribonucleic acid (RNA) interference (RNAi) therapeutics. The Company is focused on the use of its N-acetylgalactosamine (GalNAc)-conjugate platform for delivery of small interfering RNAs (siRNAs).
Receive News & Ratings for Alnylam Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alnylam Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.